Stefan Beyer, President and Managing Director: Our Statement on COVID-19

News
Published: 7 May 2020

As the world navigates the uncertainty of COVID-19, we wanted to offer some reassurance regarding the operations at Vibalogics.

Our COVID-19 response team continues to monitor the situation to ensure the appropriate measures are to be taken to keep our employees safe and ensure reliable services for our customers. This has, and always will be our top priority.

The current precautions we have taken include:

  • Daily meetings in order to react and respond quickly
  • Working from home where possible
  • Spatial separation for those who remain on site, minimizing meetings and size of meeting
  • Stringent hygiene measures and training
  • Controlled access to entry

At present, we are able to run business as usual. We endeavor to remain this way and continue to proactively review our robust contingency plans. As of today, we do not foresee a critical impact to operations, however if this were to change, we can reassure clients they will be kept well-informed and we will do everything possible to minimize any disruptions during this time.

If you have any questions or concerns, please speak to your usual point of contact at Vibalogics, and we will be able to help.

Best wishes,

Stefan Beyer

President & Managing Director

 

All actions taken by Vibalogics are under the guidance of the German Government and Health Authorities.

We’re the ideal CDMO for your Virotherapy project

Get in touch

SERVICE OFFERING

Looking for something different?

Vibalogics can assist you through a comprehensive service portfolio – ensuring success of your virotherapy, beginning with process development and technical transfer feasibility, through cGMP production and validation.

Related

What to read next

Vibalogics Completes Major Milestone in $5…

Vibalogics' expansion will provide added capacity and scalable clinical solutions for virotherapy ma…

The Medicine Maker: A New Focus for Cancer…

The Medicine Maker recently featured Joe Sinclair, Vice President, Business Development & Corporat…

GMP Manufacturing of Oncolytic Viruses: Cr…

The oncolytic virus (OV) sector needs to overcome several challenges to bring transformative cancer th…